Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Ptf1a Promoter-Driven Cre Expression During Spermatogenesis Causes Germline Recombination
Wang, Jiale, Wang, Oliver, Bi, Yan, Wang, Ying, Crawford, Howard, Ji, Baoan, Wang, Jiale , Wang, Jiale , Wang, Jiale, Wang, Oliver, Bi, Yan, Wang, Ying, Crawford, Howard, Ji, Baoan

Mayo Clinic

Pancreas | February 23, 2022 | Volume: 51 | Issue: 1 | Pages: 90-93

10.1097/mpa.0000000000001961 | PMID 35195600 Get It

Objectives Two independently developed Ptf1a-Cre mouse lines, Ptf1atm1(cre)Hnak and Ptf1atm1(Cre)Cvw, are widely used in pancreatic research. Recently, Ptf1atm1(cre)Hnak line was reported to transmit unwanted paternal recombination. We aimed to investigate whether this exists in the Ptf1atm1(Cre)Cvw line. Methods Ptf1atm1(Cre)Cvw mice were crossed with R26-LSL-LacZ reporter mice. DNA recombination and gene expression were examined by recombination-specific polymerase chain reaction, reverse transcription–polymerase chain reaction, and X-Gal staining. Results R26 locus recombination was detected in the pancreas as well as the testes and sperm of the double transgenic mice. Positive ptf1a mRNA expression from testes revealed that there was endogenous Ptf1a promoter activity in this extrapancreatic tissue. Of the 15 progenies that inherited LacZ from the male double transgenic mice, 4 (26.7%) were positive for complete whole-body recombination. The presence of recombination in R26 only mice suggested that the recombination occurred before meiosis. Conclusions Paternal germline recombination exists in the Ptf1atm1(Cre)Cvw mouse line. Ptf1a promoter-driven Cre expression during spermatogenesis before meiosis is the cause of germline recombination. Therefore, when male Ptf1a-Cre mice are used in compound mice breeding, it is necessary to genotype not only floxed alleles but also recombined alleles to examine unwanted recombinations.
Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women
Gaffey, Allison E. , Cavanagh, Casey E. , Rosman, Lindsey , Wang, Kaicheng , Deng, Yanhong , Sims, Mario , O’Brien, Emily C., Chamberlain, Alanna M. , Mentz, Robert J. , Glover, LáShauntá M. , Burg, Matthew M. , Glover, LáShauntá , Glover, LáShauntá M. , Chamberlain, Alanna M , Wang, Kaicheng , Mentz, Robert J , Gaffey, Allison E. , Cavanagh, Casey E. , Rosman, Lindsey , Deng, Yanhong , Sims, Mario , O’Brien, Emily C., Glover, LáShauntá M. , Burg, Matthew

Mayo Clinic

Journal of the American Heart Association | February 22, 2022 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/jaha.121.022514 | PMID 35191315 Get It

Background Associations between depression, incident heart failure (HF), and mortality are well documented in predominately White samples. Yet, there are sparse data from racial minorities, including those who are women, and depression is underrecognized and undertreated in the Black population. Thus, we examined associations between baseline depressive symptoms, incident HF, and all‐cause mortality across 10 years. Methods and Results We included Jackson Heart Study (JHS) participants with no history of HF at baseline (n=2651; 63.9% women; median age, 53 years). Cox proportional hazards models tested if the risk of incident HF or mortality differed by clinically significant depressive symptoms at baseline (Center for Epidemiological Studies–Depression scores ≥16 versus <16). Models were conducted in the full sample and by sex, with hierarchical adjustment for demographics, HF risk factors, and lifestyle factors. Overall, 538 adults (20.3%) reported high depressive symptoms (71.0% were women), and there were 181 cases of HF (cumulative incidence, 0.06%). In the unadjusted model, individuals with high depressive symptoms had a 43% greater risk of HF ( P =0.035). The association remained with demographic and HF risk factors but was attenuated by lifestyle factors. All‐cause mortality was similar regardless of depressive symptoms. By sex, the unadjusted association between depressive symptoms and HF remained for women only ( P =0.039). The fully adjusted model showed a 53% greater risk of HF for women with high depressive symptoms ( P =0.043). Conclusions Among Black adults, there were sex‐specific associations between depressive symptoms and incident HF, with greater risk among women. Sex‐specific management of depression may be needed to improve cardiovascular outcomes.
An IL-9–pulmonary macrophage axis defines the allergic lung inflammatory environment
Fu, Yongyao , Wang, Jocelyn , Zhou, Baohua , Pajulas, Abigail , Gao, Hongyu , Ramdas, Baskar , Koh, Byunghee , Ulrich, Benjamin J. , Yang, Shuangshuang , Kapur, Reuben , Licona-Limón, Paula , Takatsuka, Shogo , Kitamura, Daisuke , Kaplan, Mark H. , Renauld, Jean-Christophe , Paczesny, Sophie , Liu, Yunlong , Tighe, Robert M , Licona-Limón, Paula , Flavell, Richard A , Takatsuka, Shogo , Tepper, Robert S , Sun, Jie , Kaplan, Mark H , Tighe, Robert M. , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | February 18, 2022 | Volume: 7 | Issue: 68 | Pages: No page available

10.1126/sciimmunol.abi9768 | PMID 35179949 Get It

Despite IL-9 functioning as a pleiotropic cytokine in mucosal environments, the IL-9–responsive cell repertoire is still not well defined. Here, we found that IL-9 mediates proallergic activities in the lungs by targeting lung macrophages. IL-9 inhibits alveolar macrophage expansion and promotes recruitment of monocytes that develop into CD11c + and CD11c − interstitial macrophage populations. Interstitial macrophages were required for IL-9–dependent allergic responses. Mechanistically, IL-9 affected the function of lung macrophages by inducing Arg1 activity. Compared with Arg1-deficient lung macrophages, Arg1-expressing macrophages expressed greater amounts of CCL5. Adoptive transfer of Arg1 + lung macrophages but not Arg1 − lung macrophages promoted allergic inflammation that Il9r −/− mice were protected against. In parallel, the elevated expression of IL-9, IL-9R, Arg1, and CCL5 was correlated with disease in patients with asthma. Thus, our study uncovers an IL-9/macrophage/Arg1 axis as a potential therapeutic target for allergic airway inflammation.
Social risk factors predicting outcomes of cervical myelopathy surgery
Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Turner, Jay D.

Mayo Clinic

Journal of Neurosurgery: Spine | February 18, 2022 | Volume: 37 | Issue: 1 | Pages: 41-48

10.3171/2021.12.spine21874 | PMID 35090132 Get It

OBJECTIVE Combinations of certain social risk factors of race, sex, education, socioeconomic status (SES), insurance, education, employment, and one’s housing situation have been associated with poorer pain and disability outcomes after lumbar spine surgery. To date, an exploration of such factors in patients with cervical spine surgery has not been conducted. The objective of the current work was to 1) define the social risk phenotypes of individuals who have undergone cervical spine surgery for myelopathy and 2) analyze their predictive capacity toward disability, pain, quality of life, and patient satisfaction–based outcomes. METHODS The Cervical Myelopathy Quality Outcomes Database was queried for the period from January 2016 to December 2018. Race/ethnicity, educational attainment, SES, insurance payer, and employment status were modeled into unique social phenotypes using latent class analyses. Proportions of social groups were analyzed for demonstrating a minimal clinically important difference (MCID) of 30% from baseline for disability, neck and arm pain, quality of life, and patient satisfaction at the 3-month and 1-year follow-ups. RESULTS A total of 730 individuals who had undergone cervical myelopathy surgery were included in the final cohort. Latent class analysis identified 2 subgroups: 1) high risk (non-White race and ethnicity, lower educational attainment, not working, poor insurance, and predominantly lower SES), n = 268, 36.7% (class 1); and 2) low risk (White, employed with good insurance, and higher education and SES), n = 462, 63.3% (class 2). For both 3-month and 1-year outcomes, the high-risk group (class 1) had decreased odds (all p < 0.05) of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Being in the low-risk group (class 2) resulted in an increased odds of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Neither group had increased or decreased odds of being satisfied with surgery. CONCLUSIONS Although 2 groups underwent similar surgical approaches, the social phenotype involving non-White race/ethnicity, poor insurance, lower SES, and poor employment did not meet MCIDs for a variety of outcome measures. This finding should prompt surgeons to proactively incorporate socially conscience care pathways within healthcare systems, as well as to optimize community-based resources to improve outcomes and personalize care for populations at social risk.
A hedonic orexigenic subnetwork within the human hippocampus
Barbosa, Daniel A. N. , Gattas, Sandra , Salgado, Juliana S. , Kuijper, Fiene Marie , Leuze, Christoph , Rapp, Paul E. , Malenka, Robert C. , Miller, Kai J. , Halpern, Casey H. , Wang, Allan R. , Huang, Yuhao , Kakusa, Bina Wasunga , Luczak, Artur , Heifets, Boris Dov , Bohon, Cara , McNab, Jennifer A.

Mayo Clinic

No container title available | February 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1315996/v1 Get It

Abstract Only recently has the rodent hippocampus been implicated in orexigenic appetitive processing1,2. This function has been found to be mediated at least in part by lateral hypothalamic inputs involving an orexigenic neuropeptide, melanin-concentrating hormone3. This circuit remains elusive in humans. Here, we combine tractography, intracranial electrophysiology, cortico-subcortical evoked potentials, and brain-clearing 3D histology to identify an orexigenic circuit involving the lateral hypothalamus converging in a hippocampal subregion. We found that low-frequency power is modulated by sweet-fat food cues and this modulation was specific to the dorsolateral hippocampus. Lastly, structural and functional analyses of this circuit in a human cohort exhibiting dysregulated eating behavior revealed connectivity that was inversely related to body mass index. Collectively, this multimodal approach describes an orexigenic subnetwork within the human hippocampus implicated in obesity and related eating disorders.
Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).
Hauser, Christine , Tan, Winston , Du, Pan , Ng, Nicole , Bukczynska, Patricia , Foroughi, Siavash , Graham, Lisa-Jane K., Jia, Shidong , Fettke, Heidi , Kwan, Edmond M. , Dai, Chao , Zheng, Tiantian , Wang, Amy , Horvath, Lisa G. , Mahon, Kate Lynette , Kohli, Manish , Azad, Arun

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 153-153

10.1200/jco.2022.40.6_suppl.153 Get It

153 Background: The prognostic significance of DDR alterations in mCRPC remains unclear, with conflicting data from prior reports. Whether DDR alterations are predictive of outcomes with therapeutic agents other than PARP inhibitors in mCRPC is also poorly understood. With increasing use of molecular profiling in mCRPC, understanding the full prognostic and predictive utility of plasma DDR alterations is paramount. Methods: A next-generation sequencing Predicine liquid biopsy assay was used to profile cfDNA and germline DNA in 407 mCRPC patients (pts) from two independent international cohorts (n=162 Australia, n=245 US). DDR genes profiled were BRCA2, ATM, BRCA1, MLH1 and MSH2. Kaplan-Meier survival estimates and multivariable Cox regression analyses were used to assess associations between DDR alterations and clinical outcomes including PSA response rate (PSA RR), progression-free survival and overall survival (OS). Results: Median age was 74 (IQR 67-79), with median follow up 74 months and median OS 23 months. 65/407 (16%) harboured pathogenic DDR alterations, including 21 patients with ³1 alteration. Frequency of genomic aberrations are shown in the table. BRCA2 alterations were further classified as heterozygous loss (66%), homozygous loss (14%), monoallelic mutation (11%) and biallelic mutation/loss of heterozygosity (9%). Aberrations in any DDR gene, ATM, MLH1 + MSH2 or BRCA2 were associated with shorter OS on univariable analysis, but only any DDR or BRCA2 aberration remained significant upon adjusting for clinical prognosticators and ctDNA fraction (Table). Pre-treatment BRCA2 aberration was associated with significantly shorter OS and lower PSA RR compared to BRCA2 wt for pts receiving an AR pathway inhibitor (ARPI) (18 vs 32 months, p=0.006; 36 vs 60%, p=0.04 respectively) but not for taxane chemotherapy (17 vs 20 months, p=0.3; 45 vs 66, p=0.1 respectively). Conclusions: Detection of an aberration in any DDR gene or BRCA2 was an independent poor prognostic factor across 2 large independent cohorts of mCRPC patients. Intriguingly, patients with a BRCA2 alteration appeared to have worse outcomes with ARPI but not chemotherapy, suggesting predictive utility of DDR profiling. Our data collectively speak to the potential role of DDR alterations, in particular BRCA2, as prognostic and/ or predictive biomarkers in mCRPC.[Table: see text]
Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).
Knox, Andrea, Hauser, Christine , Bukczynska, Patricia , Ng, Nicole , Foroughi, Siavash , Graham, Lisa-Jane K., Tan, Winston , Du, Pan , Jia, Shidong , Fettke, Heidi , Mahon, Kate Lynette , Zheng, Tiantian , Dai, Chao , Horvath, Lisa G. , Kohli, Manish , Azad, Arun , Kwan, Edmond M. , Wang, Amy

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 150-150

10.1200/jco.2022.40.6_suppl.150 Get It

150 Background: With the evolving use of targeted therapies exploiting genomic vulnerabilities in mCRPC, screening patients for sensitizing alterations is of increasing relevance. However, the influence of age on the detection of relevant genomic alterations is incompletely understood. In this study, we compared the cell-free DNA (cfDNA) profiles of younger (age <70) versus older (age ≥70) men with mCRPC and assessed the relative prognostic impact of common genomic alterations. Methods: A next-generation sequencing-based Predicine cfDNA assay was used to profile 276 mCRPC patients from two independent international cohorts. The frequency of genomic alterations across age categories was compared using the chi-squared test, while circulating tumour DNA fraction (ctDNA%) was compared using the Mann–Whitney U test. Cox proportional hazards analysis with interaction testing was used to assess the association between age, genomic alteration and overall survival. Results: The median age of the combined cohort was 72 years (IQR 66-78), with 170 (62%) patients ≥70 years old. Despite differences in baseline characteristics (poorer performance status in older patients, higher Gleason score and de novo metastatic disease in younger patients), there was no significant difference in ctDNA% (median 22% vs 30%, p=0.6). We observed similar frequencies of genomic alterations across the 10 most commonly aberrant genes, including AR (<70 vs ≥70: 46% vs 49%, p=0.6), TP53 (40% vs 36%, p=0.6), BRCA2 (29% vs 21%, p=0.13) and PTEN (39% vs 35%, p=0.5). This similarity persisted when analysing mutations and copy number alterations in isolation. While driver alterations in both age categories were strongly associated with unfavourable outcomes (Table), an exploratory analysis revealed that copy number gain in PIK3CA may have a worse prognostic impact in younger men ( p for interaction = 0.03), with a lesser effect observed in AR gain ( p = 0.1) and MYC gain ( p = 0.1). Conclusions: The genomic profiles of pertinent alterations between younger and older men are comparable. Certain genomic alterations may carry a worse prognosis in younger men. Patients should be considered for precision medicine assessment and directed therapies, regardless of age. [Table: see text]
Artificial Intelligence and Cardiovascular Genetics
Krittanawong, Chayakrit , Johnson, Kipp W. , Choi, Edward , Kaplin, Scott , Venner, Eric , Murugan, Mullai , Glicksberg, Benjamin S. , Amos, Christopher I. , Schatz, Michael C. , Tang, W.H. Wilson , Glicksberg, Benjamin , Amos, Christopher I , Schatz, Michael C , Tang, W H Wilson , Venner, Eric , Wang, Zhen

Mayo Clinic

Life | February 14, 2022 | Volume: 12 | Issue: 2 | Pages: 279

10.3390/life12020279 | PMID 35207566 Get It

Polygenic diseases, which are genetic disorders caused by the combined action of multiple genes, pose unique and significant challenges for the diagnosis and management of affected patients. A major goal of cardiovascular medicine has been to understand how genetic variation leads to the clinical heterogeneity seen in polygenic cardiovascular diseases (CVDs). Recent advances and emerging technologies in artificial intelligence (AI), coupled with the ever-increasing availability of next generation sequencing (NGS) technologies, now provide researchers with unprecedented possibilities for dynamic and complex biological genomic analyses. Combining these technologies may lead to a deeper understanding of heterogeneous polygenic CVDs, better prognostic guidance, and, ultimately, greater personalized medicine. Advances will likely be achieved through increasingly frequent and robust genomic characterization of patients, as well the integration of genomic data with other clinical data, such as cardiac imaging, coronary angiography, and clinical biomarkers. This review discusses the current opportunities and limitations of genomics; provides a brief overview of AI; and identifies the current applications, limitations, and future directions of AI in genomics.
Resident Rotation Scheduling for Categorical Internal Medicine Residency Program
Wang, Feifan , Huang, Yu-Li , Ju, Feng , Grega, Jaimie C., Wang, Feifan

Mayo Clinic

IEEE Robotics and Automation Letters | February 12, 2022 | Volume: 7 | Issue: 2 | Pages: 4142-4148

10.1109/lra.2022.3150515 Get It

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
D’Amico, Thomas A., Bentrem, David J. , Cooke, David T. , Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Fanta, Paul T. , Farjah, Farhood , Gerdes, Hans, Hochwald, Steven N. , Hofstetter, Wayne L. , Ilson, David H. , Keswani, Rajesh N. , Kleinberg, Lawrence , Lacy, Jill , Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael J. , Mulcahy, Mary F. , Park, Haeseong , Poultsides, George A. , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Wang, Hanlin L. , Wiesner, Georgia L. , Willett, Christopher G. , Yakoub, Danny , Yoon, Harry H. , McMillian, Nicole R., Pluchino, Lenora A. , Yoon, Harry, Ajani, Jaffer A. , Bentrem, David J. , Chao, Joseph , Gibson, Michael K. , Kim, Sunnie S. Y. , Klempner, Samuel J. , Outlaw, Darryl Alan , Perry, Kyle A. , Pimiento, José M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 7, 2022 | Volume: 20 | Issue: 2 | Pages: 167-192

10.6004/jnccn.2022.0008 | PMID 35130500 Get It

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed death-ligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.